BMI View: There have been a number of positive developments in international cooperation for
Uzbekistan's pharmaceutical sector in recent months. Having identified the pharmaceutical sector as a key
area of economic growth, the Uzbek government has been encouraging do ..."
BMI View: Our projections for the Uzbek pharmaceutical and healthcare markets going into 2014 are
broadly bearish. The country continues to rank as the least attractive in the region in our RRR ratings
matrix, and real GDP growth is set to decline. We note that there ..."
BMI View: As the most populous state in Central Asia, with a population expected to increase to 29.8mn by
2017, we expect interest in the pharmaceutical and healthcare markets to increase. However, Uzbekistan
has a number of obstacles to overcome before it will presen ..."
BMI View: We expect interest in Uzbekistan's pharmaceutical market to increase over the coming
decades, both from the point of view of imports and local involvement in drug manufacturing. The
government is increasingly aiming to attract foreign players through tax and other inc ..."
BMI View: While Uzbekistan's pharmaceutical market is expected to expand substantially, albeit from a low base, the operating environment will continue to remain risky due to the unpredictable economic and political situation as much as to regulations biased in favour of local in ..."
We maintain the view that risk-averse pharmaceutical, healthcare and medical device companies should avoid Uzbekistan . While the country has a definite need for pharmaceuticals and medical devices, the regulatory environment remains opaque and state-dominated. Moreover, the gove ..."
BMI View: Risk-averse pharmaceutical, healthcare and medical device companies should avoid
Uzbekistan. Authorities in the Central Asian country are looking to restrict imported products and boost
local production. Regulations are opaque, the influence of the stat ..."